Bixby program joins global effort to develop HIV/AIDS vaccine

The UCSF Bixby Center's partnership with the University of Zimbabwe (UZ) recently joined a global research effort to develop a safe and effective vaccine to prevent HIV. The program's research site in Chitungwiza, Zimbabwe, is joining the HIV Vaccine Trials Network (HVTN), the world's largest publicly funded international collaboration facilitating the development of HIV vaccines. The U.S. National Institute of Allergy and Infectious Diseases is the network's main sponsor.

The UZ-UCSF site in Chitungwiza will expand to support its growth in HIV vaccine research. This infrastructure development will be complete by 2015, with the first study expected to start in spring 2015. These will be the first ever HIV-related vaccine clinical trials conducted in Zimbabwe.

The UZ-UCSF team is excited to join HVTN's network of clinical research sites at leading research institutions on five continents.